Pharmacological characterization and binding modes of novel racemic and optically active phenylalanine-based antagonists of AMPA receptors

被引:4
作者
Szymanska, Ewa [1 ]
Nielsen, Birgitte [2 ]
Johansen, Tommy N. [2 ]
Moral, Ana Maria Cunado [2 ]
Pickering, Darryl S. [2 ]
Szczepanska, Katarzyna [1 ]
Mickowska, Anna [1 ]
Kiec-Kononowicz, Katarzyna [1 ]
机构
[1] Jagiellonian Univ, Med Coll, Dept Technol & Biotechnol Drugs, Medyczna 9, PL-30688 Krakow, Poland
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK-2100 Copenhagen O, Denmark
关键词
Ionotropic glutamate receptors; AMPA; GluA2; Phenylalanine; Competitive antagonist; Chiral resolution; Molecular modeling; CHIRAL STATIONARY-PHASE; GLUTAMATE RECEPTORS; ABSOLUTE STEREOCHEMISTRY; MOLECULAR PHARMACOLOGY; NEUROLOGICAL DISEASE; KAINATE RECEPTORS; CRYSTAL-STRUCTURE; ACID; RESOLUTION; DERIVATIVES;
D O I
10.1016/j.ejmech.2017.07.007
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In order to map out molecular determinants for the competitive blockade of AMPA receptor subtypes, a series of racemic aryl-substituted phenylalanines was synthesized and pharmacologically characterized in vitro at native rat ionotropic glutamate receptors. Most of the compounds showed micromolar affinity and preference for AMPA receptors. Individual stereoisomers of selected compounds were further evaluated at recombinant homomeric rat GluA2 and GluA3 receptors. The most potent compound, (-)-2-amino-3-(6-chloro-2',5'-dihydroxy-5-nitro-[1,1'-biphenyl]-3-yl)proPanoic acid, the expected R-isomer showing K-i of 1.71 mu M at the GluA2 subtype, was found to competitively antagonize GluA2(Q)(i) receptors in TEVC electrophysiological experiments (K-b = 2.13 mu M). Molecular docking experiments allowed us to compare two alternative antagonist binding modes for the synthesized phenylalanines at the GluA2 binding core, showing the direction for further structural modifications. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:874 / 883
页数:10
相关论文
共 47 条
[1]   The Structure of (-)-Kaitocephalin Bound to the Ligand Binding Domain of the (S)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA)/Glutamate Receptor, GluA2 [J].
Ahmed, H. Ahmed ;
Hamada, Makoto ;
Shinada, Tetsuro ;
Ohfune, Yasufumi ;
Weerasinghe, Laksiri ;
Garner, Philip P. ;
Oswald, Robert E. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (49) :41007-41013
[2]   AMPA receptor potentiators as novel antidepressants [J].
Alt, A ;
Witkin, JM ;
Bleakman, D .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (12) :1511-1527
[3]   A role for AMPA receptors in mood disorders [J].
Alt, A ;
Nisenbaum, ES ;
Bleakman, D ;
Witkin, JM .
BIOCHEMICAL PHARMACOLOGY, 2006, 71 (09) :1273-1288
[4]  
[Anonymous], 2003, PYMOL MOL GRAPH SYST
[5]  
[Anonymous], 2016, SMALL MOL DRUG DISC
[6]   COVALENTLY BONDED TEICOPLANIN CHIRAL STATIONARY-PHASE FOR HPLC ENANTIOSEPARATIONS [J].
ARMSTRONG, DW ;
LIU, YB ;
EKBORGOTT, KH .
CHIRALITY, 1995, 7 (06) :474-497
[7]   Facile liquid chromatographic enantioresolution of native amino acids and peptides using a teicoplanin chiral stationary phase [J].
Berthod, A ;
Liu, YB ;
Bagwill, C ;
Armstrong, DW .
JOURNAL OF CHROMATOGRAPHY A, 1996, 731 (1-2) :123-137
[8]  
Bleakman D., 2007, CNS & Neurological Disorders-Drug Targets, V6, P117, DOI 10.2174/187152707780363258
[9]   Glutamate receptors and pain [J].
Bleakman, David ;
Alt, Andrew ;
Nisenbaum, Eric S. .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2006, 17 (05) :592-604
[10]   Ionotropic Glutamate Receptors & CNS Disorders [J].
Bowie, Derek .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2008, 7 (02) :129-143